Given that APOA-I and APOE share common receptors in the CNS (such as ABCA1, SR-BI, and ABCG1), these findings further highlight the potential for APOA-I to serve as a substitute therapy for APOE functional deficiency in AD patients carrying the APOE4 genotype. The gene discussed is APOE; the disease is Alzheimer disease.